Eric Stanek, PharmD

Original Contribution

Costs and Healthcare Resource Utilization for Obstructive Hypertrophic Cardiomyopathy With Septal Reduction Therapy

10/25/2022

Michael Butzner , DrPH, MPH;

Martin S. Maron , MD;

Phil Sarocco , MSc;

Eric Stanek , PharmD;

Laura A. Robertson , MD;

Chia-Chen Teng ;

Hiangkiat Tan ;

Patients with obstructive hypertrophic cardiomyopathy (oHCM) and severe refractory symptoms may require invasive septal reduction therapies (SRTs), either surgical septal myectomy (SM) or transcatheter alcohol septal ablation (ASA). The main...

Patients with obstructive...

10/25/2022

Journal of Invasive Cardiology

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

March 27 ⁠–⁠ March 30

See Full Calendar

Eric Stanek, PharmD

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products